Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Novo Nordisk (NVO) (OTCPK:NONOF) ADRs traded higher in the premarket on Wednesday after the Danish drugmaker released full ...

Novo Nordisk A/S (NVO) investors who had anticipated that the stock could continue outperforming the market were likely disappointed. Accordingly, NVO has underperformed the S&P 500 (SPX ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.

A U.S. Senate panel criticized Novo Nordisk for the high prices of Ozempic ... Medicaid Security announced the results of ...

Bernstein analyst Florent Cespedes maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK560.00. The company’s shares closed last Friday at ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...